Wednesday, June 1, 2016

BRIEF-Biogen's Alzheimer drug Aducanumab Accepted into EMA's PRIME Program

* Biogen's Investigational Alzheimer's Disease Treatment

Aducanumab Accepted Into European Medicines Agency's Prime

Program

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)